RJA
DWTX

Raymond James & Associates’s Dogwood Therapeutics DWTX Stock Holding History

Raymond James & Associates’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.2K Buy
1,224
+24
+2% +$124 ﹤0.01% 3981
2024
Q2 		$6.45K Hold
1,200
– – ﹤0.01% 3938
2024
Q1 		$14.4K Hold
1,200
– – ﹤0.01% 3889
2023
Q4 		$17.3K Hold
1,200
– – ﹤0.01% 3776
2023
Q3 		$27.7K Hold
1,200
– – ﹤0.01% 3711
2023
Q2 		$41.4K Hold
1,200
– – ﹤0.01% 3726
2023
Q1 		$11K Hold
1,200
– – ﹤0.01% 3833
2022
Q4 		$7.08K Sell
1,200
-200
-14% -$1.51K ﹤0.01% 3866
2022
Q3 		$13K Buy
+1,400
New +$197K ﹤0.01% 3838

Other funds holding DWTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RFC
Regions Financial Corp Birmingham, Alabama $15.4B AUM 21.7% 1-Year Est. Return

Raymond James & Associates's DWTX Position: Q3 2024 in Review

Raymond James & Associates increased its Dogwood Therapeutics (DWTX) stake by 2% in Q3 2024, buying an estimated $124 and bringing the position to 1,224 shares worth $5.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3981.

Raymond James & Associates first reported a position in DWTX in Q3 2022 and has held it in 9 quarters since. The position peaked at $41.4K in Q2 2023. 24 funds tracked by Wall St. Rank hold DWTX as of Q3 2024.

  • Raymond James & Associates held 1,224 shares of Dogwood Therapeutics worth $5.2K as of Q3 2024.
  • Raymond James & Associates bought 24 Dogwood Therapeutics shares in Q3 2024, an estimated $124.
  • Dogwood Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3981 holding.
  • Raymond James & Associates first reported a position in Dogwood Therapeutics in Q3 2022 and has held it in 9 quarters since.
  • Raymond James & Associates's Dogwood Therapeutics position peaked at $41.4K in Q2 2023.
  • 24 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.